Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Dagogo-Jack

Endocrinology, Diabetes & Metabolism Memphis, TN Medical Doctor

NPI 1194782235 CMS profile 144719

880 Madison Ave, Memphis, TN 38103

Open in the dashboard

General payments

$407,079

257 records reported · program years 2019–2025

Research payments

$70,310

Paid to them · 56 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$68,871 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Samuel Dagogo-Jack of Memphis, TN is reported in the CMS Open Payments database as having received $407,079 across 257 general payments and $70,310 in research payments paid to them. Separately, studies naming them as principal investigator received $68,871 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $49,422 46
2024 General $14,496 21
2024 Research $10,200 4
2023 General $19,388 12
2023 Research $1,900 1
2022 General $43,792 28
2022 Research $26,730 20
2021 General $42,846 16
2021 Research $24,170 24
2020 General $68,207 36
2020 Research $7,310 7
2019 General $168,929 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Dagogo-Jack
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Samuel Dagogo-Jack were reported at $49,422. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Samuel Dagogo-Jack Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $168,929 $494 $123–$2,253 $163
2020 $68,207 $335 $85–$1,841 $114
2021 $42,846 $398 $88–$1,981 $132
2022 $43,792 $364 $88–$1,568 $149
2023 $19,388 $420 $113–$1,614 $160
2024 $14,496 $440 $121–$1,646 $164
2025 $49,422 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $231,058 142 payments
  2. Sanofi-Aventis U.S. LLC $72,362 18 payments
  3. Madrigal Pharmaceuticals $60,060 62 payments
  4. Novo Nordisk Inc $13,766 8 payments
  5. Janssen Pharmaceuticals, Inc $10,095 10 payments
  6. Medtronic, Inc. $9,600 3 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $4,520 7 payments
  8. Medtronic MiniMed, Inc. $2,400 1 payment
  9. AstraZeneca Pharmaceuticals LP $2,148 2 payments
  10. Abbott Laboratories $750 1 payment
  11. Other $320 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $231,623 62 payments
  2. Travel and Lodging $86,833 110 payments
  3. Consulting Fee $77,701 31 payments
  4. Honoraria $6,875 1 payment
  5. Food and Beverage $3,482 52 payments
  6. Education $565 1 payment
Products named General payments · program years 2019–2025
  1. REZDIFFRA Liver Disease $44,847 42 payments
  2. STEGLATRO $42,359 44 payments
  3. SOLIQUA 100/33 $38,429 5 payments
  4. TOUJEO $33,933 13 payments
  5. LANTUS $19,256 6 payments
  6. JANUVIA $18,628 26 payments
  7. REZDIFFRA Liver Disease $14,389 19 payments
  8. Victoza $5,205 3 payments
  9. CYCLOSET $4,520 7 payments
  10. FARXIGA $2,148 2 payments
  11. Other $1,024 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $70,310 56 payments

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record